GENETIC SIGNATURES LIMITED Financials Genetic Signatures Limited
Equities
GSS
AU000000GSS4
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 AUD | +0.72% |
|
+2.94% | +60.92% |
| Apr. 30 | Genetic Signatures Appoints Interim CEO | MT |
| Apr. 28 | Genetic Signatures' Sales Drop in Fiscal Q3 | MT |
Valuation
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 306.6 | 157.2 | 166.3 | 75.29 | 130.5 | - | - |
| Enterprise Value (EV) 1 | 276.2 | 127.5 | 166.3 | 75.29 | 110.5 | 123.5 | 131.6 |
| P/E ratio | -131 x | 90.9 x | 55 x | -5.36 x | -7.45 x | -19.4 x | 233 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 21.6 x | 5.56 x | - | 4.44 x | 12.9 x | 4.98 x | 3.02 x |
| EV / Revenue | 19.5 x | 4.51 x | - | 4.44 x | 10.9 x | 4.72 x | 3.05 x |
| EV / EBITDA | -236 x | 45.8 x | 37.1 x | -4.27 x | -6.91 x | -25.2 x | 50.6 x |
| EV / FCF | -23.3 x | -163 x | 24.4 x | - | -9.37 x | -9.5 x | -16.3 x |
| FCF Yield | -4.29% | -0.62% | 4.1% | - | -10.7% | -10.5% | -6.15% |
| Price to Book | - | - | 3.03 x | - | 3.2 x | 3.83 x | 3.76 x |
| Nbr of stocks (in thousands) | 142,615 | 142,907 | 143,390 | 143,410 | 186,487 | - | - |
| Reference price 2 | 2.150 | 1.100 | 1.160 | 0.5250 | 0.7000 | 0.7000 | 0.7000 |
| Announcement Date | 8/27/20 | 8/24/21 | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.17 | 28.28 | - | 16.94 | 10.1 | 26.2 | 43.2 |
| EBITDA 1 | -1.17 | 2.782 | 4.481 | -17.64 | -16 | -4.9 | 2.6 |
| EBIT 1 | -2.053 | 1.792 | 3.082 | -19.17 | -17.7 | -6.8 | 0.6 |
| Operating Margin | -14.49% | 6.34% | - | -113.16% | -175.25% | -25.95% | 1.39% |
| Earnings before Tax (EBT) 1 | -2.086 | 1.756 | 3.063 | -14.05 | -17.5 | -6.8 | 0.6 |
| Net income 1 | -2.086 | 1.756 | 3.063 | -14.05 | -17.5 | -6.8 | 0.6 |
| Net margin | -14.72% | 6.21% | - | -82.96% | -173.27% | -25.95% | 1.39% |
| EPS 2 | -0.0164 | 0.0121 | 0.0211 | -0.0980 | -0.0940 | -0.0360 | 0.003000 |
| Free Cash Flow 1 | -11.84 | -0.784 | 6.817 | - | -11.8 | -13 | -8.1 |
| FCF margin | -83.57% | -2.77% | - | - | -116.83% | -49.62% | -18.75% |
| FCF Conversion (EBITDA) | - | - | 152.13% | - | - | - | - |
| FCF Conversion (Net income) | - | - | 222.56% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/27/20 | 8/24/21 | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.704 | 10.47 | 18.93 | 9.356 | - | - | 10.8 | 6.142 | 3.604 | 6.5 |
| EBITDA 1 | -1.936 | 0.766 | 5.172 | -2.155 | - | - | - | - | -9.688 | -6.2 |
| EBIT | -2.331 | 0.278 | 4.517 | -2.725 | - | -1.619 | -6.48 | - | - | - |
| Operating Margin | -62.93% | 2.66% | 23.86% | -29.13% | - | - | -60.02% | - | - | - |
| Earnings before Tax (EBT) | -2.346 | 0.26 | 4.497 | -2.741 | - | - | - | - | - | - |
| Net income 1 | -2.346 | 0.26 | 4.497 | -2.741 | 4.701 | -1.638 | -6.48 | -7.572 | -10.47 | -7 |
| Net margin | -63.34% | 2.48% | 23.76% | -29.3% | - | - | -60.02% | -123.28% | -290.48% | -107.69% |
| EPS | - | - | - | - | 0.0320 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 8/27/20 | 2/22/21 | 8/24/21 | 2/17/22 | 8/31/22 | 2/22/23 | 8/31/23 | 2/21/24 | - |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 1.1 |
| Net Cash position 1 | 30.4 | 29.7 | - | - | 20 | 7 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | 0.4231 x |
| Free Cash Flow 1 | -11.8 | -0.78 | 6.82 | - | -11.8 | -13 | -8.1 |
| ROE (net income / shareholders' equity) | -7.38% | 3.69% | 5.39% | - | - | - | 1.6% |
| ROA (Net income/ Total Assets) | -6.75% | 3.39% | - | - | - | - | - |
| Assets 1 | 30.92 | 51.88 | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 0.3800 | - | 0.2200 | 0.1800 | 0.1900 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 2.35 | 4.98 | 2.99 | - | 2 | 2.2 | 2.4 |
| Capex / Sales | 16.58% | 17.6% | - | - | 19.8% | 8.4% | 5.56% |
| Announcement Date | 8/27/20 | 8/24/21 | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.695
AUD
Average target price
0.75
AUD
Spread / Average Target
+7.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.92% | 84.17M | |
| +8.11% | 217B | |
| +6.29% | 183B | |
| +10.92% | 131B | |
| +24.71% | 106B | |
| -0.95% | 62.16B | |
| +10.69% | 51.02B | |
| +4.81% | 50.89B | |
| -0.40% | 40.16B | |
| +1.40% | 34.79B |
- Stock Market
- Equities
- GSS Stock
- Financials Genetic Signatures Limited
